CAR-T therapy for multiple myeloma shows promise but trial ends early
NCT ID NCT04318327
First seen Apr 04, 2026 · Last updated May 08, 2026 · Updated 7 times
Summary
This early-phase study tested a new type of immunotherapy called CAR-T cells, which are the patient's own immune cells modified to attack a protein called BCMA found on myeloma cells. The trial included adults with multiple myeloma that had not responded to at least two prior treatments. The main goals were to check safety and see if the treatment could shrink the cancer. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Cente
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.